Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688282 · ClinicalTrials.gov registry record · NA
Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women--Aim 2
A NA study of Osteopenia, sponsored by Theranova, L.L.C..
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT03688282 is a NA study of Osteopenia that has completed, run by Theranova, L.L.C.. The registered enrollment target is 18 participants, below the 110-participant average among 9 other Osteopenia trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03688282, a NA study of Osteopenia, has completed, sponsored by Theranova, L.L.C..
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The wearable vibration device aims to consistently deliver vibrations directly to the hip and spine and allowing use during many everyday activities. We propose that demonstrating higher rates of compliance and consistent delivery of optimal force, with accelerometer feedback, will provide a superior alternative to whole body vibration and is plausibly more effective at preventing bone loss in postmenopausal women than vibration platforms in the home setting.
Conditions Studied
Interventions
- DEVICE Wearable vibration belt
- DEVICE Sham, wearing belt
Study Locations (1)
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-07-11 |
| Est. Completion | 2019-04-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03688282
The ClinicalTrials.gov registry entry for NCT03688282 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 110-participant average among 9 other Osteopenia trials with a reported enrollment target (84% lower). The listed sponsor is Theranova, L.L.C., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteopenia appearing as the primary indexed condition, and to 2 interventions - of which Wearable vibration belt is the first listed.
NCT03688282 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT03688282 about?
NCT03688282 is a clinical study titled "Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women--Aim 2". The wearable vibration device aims to consistently deliver vibrations directly to the hip and spine and allowing use during many everyday activities. We propose that demonstrating higher rates of compliance and consistent delivery of optimal force, with accelerometer feedback, will provide a superio...
What is the current status of trial NCT03688282?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2018-07-11. Estimated completion is 2019-04-17.
What conditions does trial NCT03688282 study?
This clinical trial studies the following conditions: Osteopenia.
What interventions are being tested in trial NCT03688282?
The interventions under investigation include: Wearable vibration belt (DEVICE), Sham, wearing belt (DEVICE).
Who is sponsoring clinical trial NCT03688282?
This trial is sponsored by Theranova, L.L.C., which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03688282 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sickle Cell Disease (SCD) Bone Pain Study
ACTIVE NOT RECRUITING · NA
-
Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk
RECRUITING
-
Melatonin and Osteogenic Loading on Osteopenia
ACTIVE NOT RECRUITING · Early Phase 1
-
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
COMPLETED · Phase 4
-
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
COMPLETED · Phase 1
-
Does Treatment of Hypovitaminosis D Increase Calcium Absorption?
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.